APGOT-EN3: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer (EC) After Platinum-Based Chemotherapy and PD(L)-1 Therapy.